Arena Updates Etrasimod Timelines, Introduces New Drug Candidate

Late-Stage S1P Modulator Data Due Later In 2021, Early In 2022

Jan 14 2021

• By Mandy Jackson

Listen to this article

CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.

Arena Pharmaceuticals, Inc. CEO Amit Munshi provided assurances during the J.P. Morgan Healthcare Conference on 13 January that the company is intensely focused on the initial opportunity for its selective S1P receptor modulator etrasimod in ulcerative colitis. But with Phase III data in UC a year or more away, the company offered up news of a new drug candidate and revealed updated timelines for etrasimod and other clinical-stage programs.

Munshi spent the bulk of his prepared remarks talking about temanogrel, an internally discovered 5-HT2A antagonist that the company plans...

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio
Jan 23 2026
• By Jessica Merrill
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Quick Listen: Scrip’s Five Must-Know Things
Dec 09 2025
• By Reed Miller
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Article Without An Author Listed
Nov 19 2025
Here is a short description.
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings
Jun 17 2026
ghghghghghjhjhjhj